Literature DB >> 14597346

Changes in biologic characteristics of breast cancer treated with high-intensity focused ultrasound.

Feng Wu1, Zhi-Biao Wang, You-De Cao, Wen-Zhi Chen, Jian-Zhong Zou, Jin Bai, Hui Zhu, Ke-Quan Li, Cheng-Bing Jin, Fang-Lin Xie, Hai-Bing Su, Gen-Wu Gao.   

Abstract

Proliferation, invasion, immortalization and metastasis are the main malignant characteristics of cancer. Previous studies have shown that high-intensity focused ultrasound (US), or HIFU, can induce irreversible damage both to breast cancer cells and to tumor blood vessels. However, light microscopy alone may not always show this clearly. In this study, molecular biologic techniques were used to examine any changes in molecular markers associated with malignant behavior after exposure to HIFU. A total of 48 women with breast cancer were randomized to a control group (mastectomy) and a HIFU group (HIFU followed by mastectomy). Immunohistochemical staining, messenger RNA (mRNA) in situ hybridization and telomere-repeat amplification protocol-enzyme-linked immunosorbent assay (TRAP-ELISA) techniques were used to detect tumor expression of proliferating cell nuclear antigen (PCNA), cell adhesion molecule CD44v6, matrix metalloproteinase-9 (MMP-9), erbB2 mRNA, and to measure telomerase activity in both groups. The results demonstrated that there were significant alterations in expression of PCNA, CD44v6, MMP-9, erbB2 mRNA, and a dramatic decrease in telomerase activity in the HIFU group. It is concluded that malignant tumor characteristics are arrested by HIFU, and that biologic factors are potential markers for assessing HIFU efficacy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14597346     DOI: 10.1016/s0301-5629(03)01034-2

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  8 in total

Review 1.  High-intensity focused ultrasound tumor ablation: review of ten years of clinical experience.

Authors:  Lian Zhang; Zhi-Biao Wang
Journal:  Front Med China       Date:  2010-08-10

2.  Multi-parametric monitoring and assessment of high-intensity focused ultrasound (HIFU) boiling by harmonic motion imaging for focused ultrasound (HMIFU): an ex vivo feasibility study.

Authors:  Gary Y Hou; Fabrice Marquet; Shutao Wang; Elisa E Konofagou
Journal:  Phys Med Biol       Date:  2014-02-20       Impact factor: 3.609

3.  Phase aberration simulation study of MRgFUS breast treatments.

Authors:  Alexis I Farrer; Scott Almquist; Christopher R Dillon; Leigh A Neumayer; Dennis L Parker; Douglas A Christensen; Allison Payne
Journal:  Med Phys       Date:  2016-03       Impact factor: 4.071

Review 4.  More than just tumor destruction: immunomodulation by thermal ablation of cancer.

Authors:  Sebastian P Haen; Philippe L Pereira; Helmut R Salih; Hans-Georg Rammensee; Cécile Gouttefangeas
Journal:  Clin Dev Immunol       Date:  2011-12-29

Review 5.  Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies.

Authors:  Renske J E van den Bijgaart; Dylan C Eikelenboom; Martijn Hoogenboom; Jurgen J Fütterer; Martijn H den Brok; Gosse J Adema
Journal:  Cancer Immunol Immunother       Date:  2016-09-01       Impact factor: 6.968

6.  M-HIFU inhibits tumor growth, suppresses STAT3 activity and enhances tumor specific immunity in a transplant tumor model of prostate cancer.

Authors:  Xiaoyi Huang; Fang Yuan; Meihua Liang; Hui-Wen Lo; Mari L Shinohara; Cary Robertson; Pei Zhong
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

7.  Evaluating the effect of high-intensity focused ultrasound therapy on liver tumors using multislice CT perfusion.

Authors:  Xinshan Cao; Xingyue Jiang
Journal:  Oncol Lett       Date:  2012-12-10       Impact factor: 2.967

Review 8.  Image-guided focused ultrasound ablation of breast cancer: current status, challenges, and future directions.

Authors:  A C Schmitz; D Gianfelice; B L Daniel; W P Th M Mali; M A A J van den Bosch
Journal:  Eur Radiol       Date:  2008-03-20       Impact factor: 7.034

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.